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Abstract
Objective—Cannabis use has been examined as a predictor of psychosis in clinical high-risk 
(CHR) samples, but little is known about the impact of other substances on this relationship.
Method—Substance use was assessed in a large sample of CHR participants (N = 370, mean age 
= 18.3) enrolled in the multisite North American Prodrome Longitudinal Study Phase 1 project. 
Three hundred and forty-one participants with cannabis use data were divided into groups: No Use 
(NU, N = 211); Cannabis Use without impairment (CU, N = 63); Cannabis Abuse/Dependence 
(CA/CD, N = 67). Participants (N = 283) were followed for ≥2 years to determine psychosis 
conversion.
Results—Alcohol (45.3%) and cannabis (38.1%) were the most common substances. Cannabis 
use groups did not differ on baseline attenuated positive symptoms. Seventy-nine of 283 
participants with cannabis and follow-up data converted to psychosis. Survival analysis revealed 
significant differences between conversion rates in the CA/CD group compared with the No Use 
(P = 0.031) and CU group (P = 0.027). CA/CD also significantly predicted psychosis in a 
regression analysis, but adjusting for alcohol use weakened this relationship.
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Conclusion—The cannabis misuse and psychosis association was confounded by alcohol use. 
Non-impairing cannabis use was not related to psychosis. Results highlight the need to control for 
other substance use, so as to not overstate the cannabis/psychosis connection.
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Introduction
A large body of research examining the relationship between substance use and psychosis 
has been generated over the past several decades. Much of this literature has focused on 
cannabis use, in particular, given that high rates of cannabis use disorders have been found 
in clinical samples of patients with psychosis (1). A recent meta-analysis found that this is 
especially true of younger, first episode psychosis cohorts (2). In addition, population- based 
studies have shown that persons who use cannabis are at increased risk for the development 
of psychotic symptoms and psychotic disorders (3, 4). In some studies, a dose-dependent 
relationship was observed, with twice the risk for those individuals with the highest 
frequency cannabis use (3). Given these findings, it was expected that a similar association 
would be found in adolescent and young adult clinical samples that are enriched for the 
development of psychosis based upon clinical and familial characteristics. Approximately 
19–39% of these clinical high-risk (CHR) individuals will go on to develop a psychotic 
disorder (5–7). Thus, CHR individuals, who present to specialized research programmes 
before the onset of psychosis, but when symptoms are beginning to develop, provide a 
unique opportunity to study the purported cannabis/psychosis connection.
However, results from CHR studies have been inconsistent. The first study (8) conducted in 
Australia with 100 ‘ultra high-risk’ young people did not find a significant relationship 
between self-reported cannabis use or dependence and risk for conversion to psychosis at a 1 
year follow-up. Similar negative findings were found in high-risk studies in North America 
(9–11) and Europe (12, 13). However, a study conducted in California (14) did find that 
CHR subjects with lifetime cannabis abuse or dependence were significantly more likely to 
develop psychosis, and Valmaggia et al. (15) found that frequent use beginning before the 
age of 15 was associated with a higher rate of transition. Some of the studies conducted thus 
far are compromised by relatively low rates of cannabis use (8, 10) and others by small 
sample sizes (9, 12–14), indicating that power issues may make drawing conclusions about 
cannabis use and psychosis risk difficult. In addition, some research groups excluded 
subjects with current cannabis dependence and rates of lifetime cannabis abuse/dependence 
were low in most studies, leaving open the possibility that level of use may mitigate the 
relationship between cannabis use and psychosis.
On a larger scale, two independent CHR consortia have reported findings on the predictors 
of psychosis conversion in their respective samples. These studies looked at DSM-IV 
diagnoses of substance abuse more broadly and did not single out any one substance. 
Reports from the European Prediction of Psychosis Study (7, 16, 17) did not find substance 
abuse to be a significant predictor of psychosis conversion. The other consortia, utilizing a 
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large sample of CHR individuals, the North American Prodrome Longitudinal Study 
(NAPLS) (6, 18), found that substance abuse in general, but not cannabis abuse specifically, 
was one of five significant predictors of psychosis conversion in that sample. This suggests 
that the relationship between cannabis and psychosis may be overestimated when not 
examined in conjunction with other substance use. Most high-risk studies to date have made 
little mention of possible confounding by other substances, although confounding factors 
such as this have been implicated in the inconsistent results found in several observational 
population-based studies of cannabis and psychosis (19). Alcohol use in particular appears 
to be the most likely potential confounder given high lifetime prevalence rates of alcohol use 
disorders (median = 20.6%) in patients with schizophrenia (20). Baseline rates of alcohol 
use are also high in CHR samples [16.7%–44.3%; (21)], and some studies have reported 
high rates of comorbid alcohol and cannabis use (9, 17).
Aims of the study
Therefore, the aims of this study were to more closely examine (i) the rates of substance use, 
in particular cannabis, in the North American Prodrome Longitudinal Study Phase 1 sample, 
(ii) the relationship between level of cannabis use and attenuated positive and negative 
symptoms of psychosis, (iii) the impact of level of cannabis use on conversion to psychosis, 
and (iv) the impact of other substance use (especially alcohol use) on the association 
between cannabis and conversion to psychosis.
Material and methods
Overview
The NAPLS 1 collaborative database was formed in 2007 and contains data on a number of 
clinical, cognitive, and functioning variables collected from eight independent research 
centers: Emory University, Harvard University, University of California – Los Angeles, 
University of California – San Diego, University of Calgary, University of North Carolina, 
Yale University, and The Zucker Hillside Hospital. The centers included in the collaborative 
database were all funded by NIMH between 2000 and 2003, and the data were collected 
between 1998 and 2005. This multisite collaboration was possible given that all sites utilized 
the same diagnostic instrument for high-risk categorization, the Structured Interview for 
Prodromal Syndromes (SIPS) (22, 23), had established interrater reliability on this 
instrument after completing a rater-training workshop, and were investigating many similar 
clinical and functioning domains (18). All sites received Institutional Review Board 
approval to contribute de-identified data to the common NAPLS database.
Sample
In total, 888 subjects were contributed to the baseline database by the eight sites. Of these, 
370 were characterized as CHR based upon the SIPS interview [same sample as Cannon et 
al. (6)]. Although the SIPS measure contains four subscales, the positive symptom scale, 
assessing unusual thoughts, suspiciousness, grandiose ideas, perceptual abnormalities, and 
conceptual disorganization, is the most relevant to diagnosing a high-risk state. To be 
included in the CHR sample, subjects had to meet the criteria for one of the following 
syndromes: (i) attenuated positive symptom (APS) syndrome, that is, one or more positive 
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symptoms in the prodromal severity range (moderate to severe, but not psychotic), occurring 
at a frequency of least once per week and that began or worsened in the year prior to 
ascertainment; (ii) brief intermittent psychotic syndrome (BIPS), that is, one psychotic level 
positive symptom that has begun in the 3 months prior to baseline that occurs at least once 
per month, but less than four times per week, and that spontaneously remits; or (iii) genetic 
high-risk and deterioration (GRD) syndrome, that is, subject has schizotypal personality 
disorder or a first degree relative with a psychotic disorder, and a 30% decline in Global 
Assessment of Functioning (GAF) score over the year prior to ascertainment.
Of 370 participants who met CHR criteria at baseline, 29 (7.8%) did not have data on 
cannabis use and were excluded from the current analyses. Of the remaining 341 subjects, 
the majority met criteria for APS (96.8%, n = 330), 10 subjects met BIPS criteria (2.9%), 
and one met GRD criteria (0.3%). The mean age of the sample is 18.3 (SD = 4.77). Fifty-
four APS subjects and four BIPS subjects did not have outcome data (17%), leaving 283 
subjects in the outcome analyses. There were more males without outcome data (20.5% vs. 
11.5%; χ2 = 4.66, P = 0.031), but no differences between those with and without outcome 
data on age, race, and rates of substance use (P = 0.09– 0.90). About a third of the sample 
(28.7%) was included in earlier published reports (10, 14).
Measures
The SIPS subscale items are rated on 7-point anchored scales with scores of 0–2 
representing none to mild level severity, scores of 3–5 representing moderate to severe level 
of severity, and scores of 6 indicating psychotic/extreme level of severity. Other clinical and 
demographic variables were collected at all sites using similar, although not always the same 
instruments. Careful attention was paid to the recoding of variables when instruments 
differed (18, 24).
All participants were interviewed with semistructured interviews using the Structured 
Clinical Interview for DSM (SCID) (25) or the Kiddie-Schedule for Affective Disorders and 
Schizophrenia (KSADS) (26) to determine rates of lifetime substance use and substance use 
disorders. Substances assessed included the following: alcohol, cannabis, hallucinogens, 
cocaine, stimulants, opioids, and hypnotics. Information on frequency or recency of 
substance use was not available. Based upon reported level of lifetime use, participants were 
divided into the following subgroups: no use, use without impairment, abuse and 
dependence. The latter two categories are based on DSM-IV (27) criteria. The ‘use without 
impairment’ classification refers to individuals who reported substance use that was not 
impairing enough to meet the criteria for a substance use disorder.
Conversion to psychosis was based upon meeting the full criteria for Presence of Psychotic 
Syndrome (POPS) on the SIPS which is defined as having a psychotic level positive 
symptom that is either seriously disorganizing or dangerous or that occurs for at least 1 
h/day for an average frequency of 4 days in the past month. IQ estimates were based on the 
Wechsler intelligence scales (28–30).
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Statistical analyses were performed with SPSS version 16 (SPSS Inc, Chicago, IL, USA) 
statistical software. One-way ANOVA and chi-square tests were conducted to compare 
groups on demographics and clinical variables. Significant ANOVAs were followed by post 
hoc tests with Bonferroni correction for multiple comparisons (P = 0.05).
The cumulative probabilities of transition to psychosis were estimated using the Kaplan–
Meier method (31) and were compared for three cannabis groups using the log-rank test: No 
Use (NU), Cannabis Use without impairment (CU), and a combined group of Cannabis 
Abuse (CA)/Cannabis Dependence (CD). Kaplan–Meier survival method estimated the 
shape of the survival function during the follow-up interval, the cumulative rate of 
conversion, and the incidence rates of conversion within successive 6-month epochs. A Cox 
regression also was conducted to examine the impact of level of cannabis use (compared 
with NU) on conversion to psychosis after adjusting for potential confounding variables 
including age at baseline, gender, SOPS positive symptom total, SOPS negative symptom 
total, and use of alcohol and drugs other than cannabis (P < 0.05).
Results
Baseline comparisons
Alcohol was the most frequently reported substance used (45.3%) followed by cannabis use 
(38.1%; See Table 1). 85% of cannabis users also reported alcohol use (63.6% alcohol use 
without impairment and 36.4% alcohol abuse/dependence). Use of drugs other than alcohol 
and cannabis was infrequent with 87–96% of subjects reporting no use of these substances.
Among cannabis users, 18.5% reported cannabis use without impairment (CU group), 13.2% 
met criteria for cannabis abuse (CA group), and 6.5% met criteria for cannabis dependence 
(CD group). The NU group was significantly younger than all three cannabis using groups 
(P ≤ 0.01), and this group had significantly lower IQ estimates than the CU group (P < 
0.01). The CD group had significantly fewer parents with greater than high school level of 
education compared with the CA and NU groups. There were no significant differences on 
gender or race (see Table 2). Given the relatively small sample sizes for the CA and CD 
groups, these two groups were combined for the rest of the analyses.
In terms of SIPS high-risk symptoms, there were no significant differences between 
cannabis use groups on attenuated positive symptoms at baseline (see Table 3). For 
attenuated negative symptoms, the NU group had significantly higher scores on Social 
Anhedonia compared with the CU group and significantly higher scores on the Decreased 
Expression of Emotion item compared with the CU and the combined CA/CD group (Table 
3). However, these results did not remain significant with correction for multiple 
comparisons (P = 0.074; P = 0.057; P = 0.090 respectively). The CU group had significantly 
higher scores than the NU group on Experience of Emotion which remained significant with 
Bonferroni correction (P = 0.038).
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Of the 341 high-risk subjects with cannabis use data, 283 (82.9%) had outcome data (NU: N 
= 174, CU: N = 51, and CA/CD: N = 58). The mean time to follow up (in months) did not 
differ between the groups: NU = 18.06 (SD = 9.65), CU = 16.19 (SD = 9.79), and CA/CD = 
16.44 (SD = 9.96; F(2) = 1.07, P = 0.35).
Of the 283 high-risk subjects with outcome data, 79 converted to psychosis during the 
follow-up period: 46 (26.4%) from the NU group, 9 (17.6%) from the CU group, and 24 
(41.4%) from the CA/ CD group. A Kaplan–Meier survival analysis revealed a significant 
difference between the rates of conversion in the CA/CD group compared with both the NU 
(log-rank test − χ2 = 4.67, P = 0.031) and CU group (log-rank test − χ2 = 4.92, P = 0.027; 
See Fig. 1). At 6 months follow-up, 17.2% (SE = 0.05) of the CA/CD group had converted 
to psychosis compared with 10.3% (SE = 0.02) in the NU group and 7.8% (SE = 0.04) in the 
CU group. At 12 months follow- up, the conversion rates were 26.6% (SE = 0.06) for the 
CA/CD group compared with 16.8% (SE = 0.03) for the NU and 15.3% (SE = 0.05) for the 
CU group. At 18 months, conversion rates were 40.5% (SE = 0.07) for CA/CD, 23.6% (SE 
= 0.03) for NU and remained the same for the CU group. By 24 months, conversion rates 
were as follows: 42.9% (SE = 0.07) CA/CD vs. 26.4% (SE = 0.04) NU vs. 24.7% (SE = 
0.08) CU.
A Cox regression was also carried out to look at the contribution of level of cannabis to 
conversion after adjusting for other predictor variables. Predictors in the model included age 
at baseline, gender, SIPS positive symptom total, SIPS negative symptom total, and the three 
levels of cannabis use. Results revealed that SIPS positive and negative symptom totals were 
significantly related to conversion (P < 0.001 and P = 0.001 respectively) as was CA/CD (P 
= 0.015). Gender, age at baseline, and CU did not significantly predict conversion to 
psychosis (P = 0.165, P = 0.929, and P = 0.369 respectively).
However, when three levels of alcohol use (no use, use without impairment, and abuse/
dependence) were included in the model, alcohol use was not significantly related to 
conversion (P ≥ 0.34) but CA/CD was no longer significantly related to conversion (P = 
0.064; See Table 4). In addition, when level of alcohol use was examined without cannabis 
use, neither alcohol use nor alcohol abuse/dependence was significant predictor of psychosis 
in regression analysis (P = 0.31 and P = 0.06 respectively). The inclusion of ‘any drug use’ 
other than cannabis (i.e., hallucinogens, cocaine, stimulants, opioids, or hypnotics; P ≥ 
0.706) did not alter the significant association between cannabis and conversion for those 
with CA/CD (P = 0.043).
Discussion
In this large sample of CHR participants, cannabis use or cannabis use disorders were not 
related to more severe attenuated positive symptoms at baseline. However, there was an 
association over follow- up between more impairing cannabis use and conversion to 
psychosis. Specifically, participants with cannabis use disorders – cannabis abuse and 
cannabis dependence – had a higher rate of conversion in a shorter period of time compared 
with the non-using subjects and subjects with cannabis use without impairment. When level 
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of cannabis use was added to a regression adjusting for baseline clinical (positive and 
negative) symptoms and demographic variables, having a cannabis use disorder was a 
significant predictor of conversion while cannabis use without impairment was not a 
predictor. These findings are consistent with some clinical cohort and epidemiological 
findings (3, 4, 14) and suggest that it is the impairing effects of cannabis that account for the 
significant relationship between cannabis misuse and psychosis. However, a second possible 
interpretation is that youngsters closest to converting are most likely to self-medicate, a 
possibility supported by the confounding effect of alcohol use. While not significantly 
related to conversion itself, taking alcohol use into account weakened the relationship 
between cannabis abuse/dependence and psychosis.
It is likely that earlier discrepant reports about the relationship of cannabis to psychosis 
onset in CHR samples have resulted from lack of attention to confounding factors such as 
level of cannabis use and simultaneous abuse of other substances. Most of the studies that 
did not find a relationship between cannabis and psychosis focused on cannabis use in 
general and did not take more severe levels of use into account that, in fact, were often 
exclusionary criteria for studies (8, 10). The findings from the current study highlight the 
importance of controlling for confounding factors that could lead to an overestimation of the 
association between cannabis and psychosis (3, 19). Adjustment for other substance use has 
been found to weaken cannabis and psychosis associations in population-based studies (32, 
33) and has been largely overlooked in CHR studies (21).
Alcohol is the predominant substance used in this sample, and rates of use are comparable to 
other North American high-risk samples (9–11) and to US population rates for 18–20-year 
olds (34). In reference to the latter, 43.8% of those 18- to 20-year olds surveyed reported 
alcohol use in the past month, 29.1% reported binge drinking, and approximately 8.5% 
reported heavy alcohol use. European samples have reported even higher rates of heavy 
alcohol use. For example, Dragt et al. (17) reported that 48% of the cannabis-using high-risk 
participants in their sample also had a diagnosed alcohol use disorder. The significance of 
this is seen in studies that show an association between heavy alcohol use in adolescence 
and emotional, behavioural, and psychosocial problems in young adulthood across cultures 
(35, 36). Given the prevalence of alcohol use in teenagers and young adults, examination of 
cannabis use is likely always confounded by the use of this substance. This is especially 
relevant given that alcohol use in adolescence has been associated with cognitive deficits 
(37, 38) and decreased white matter integrity in neuroimaging studies (39–41). Furthermore, 
while detrimental effects on white matter integrity are seen for alcohol use (and even more 
so for heavy use), this same relationship was not found for cannabis use in one longitudinal 
study of adolescents (42).
Although this sample evidenced low rates of substance use other than alcohol and cannabis 
and including other drugs in the regression did not alter the results, it is important to 
consider the impact of other drugs on the development of psychiatric symptoms. For 
example, a longitudinal population study of adolescents in Germany found associations 
between psychotic symptoms and cocaine and psychedelics (43). Furthermore, a recent 
cohort study found that methamphetamine use was associated with risk for schizophrenia 
equivalent to cannabis use (44). The findings from Kristensen et al. (14) also point to the 
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importance of looking at tobacco use as this was found to be a significant predictor of 
conversion to psychosis in that high-risk sample. Additionally, van Gastel et al. (45) found 
that cigarette smoking confounded the relationship between cannabis use and distress related 
to psychotic-like experiences in a population survey study in the Netherlands.
Limitations
It should be noted that the majority of CHR subjects have never used cannabis and about 
50% of those who do use cannabis do not report any impairing effects of use. In those 
participants who use cannabis but are not impaired to the point that a diagnosis is warranted, 
cannabis use is not related to psychosis development. However, cannabis use (and other 
substance use) in this sample reflects lifetime use and substance use was not recorded over 
the follow-up period, both of which constrain interpretation. For example, it is not known 
whether incident use or continued cannabis use over follow-up would have impacted the 
results (4, 15, 46). Frequency and quantity of cannabis use was also not recorded, which is a 
further limitation of the study and prevented us from examining a dose response relationship 
directly. A related issue is the lack of an objective measure of substance use such as urine 
analysis. Rates of other substance use aside from cannabis and alcohol were low in this 
sample (although consistent with the population rates), which limited our ability to look at 
levels of other drug abuse. Additionally, we did not have data on tobacco use, so the 
relationship between tobacco use and psychosis which has been found in other relevant 
studies could not be explored in this sample. Lastly, there are some demographic factors 
specific to this study (e.g., parental education, race) that may limit generalizability to other 
samples.
Nonetheless, this study utilizing a large multisite database sheds light on the purported 
connection between cannabis and psychosis by identifying that abuse of cannabis with 
impairing effects, rather than general recreational use, appears to place one at risk for 
psychosis when examined in isolation, although this relationship is mitigated when 
concomitant alcohol use is considered. Studies that do not control for other substance use 
may overestimate the relationship between cannabis use and psychosis. Furthermore, this 
study highlights the need for the field to focus on not only cannabis misuse, but also alcohol 
misuse, as both are highly prevalent in adolescent samples. This will have important 
implications when assessing high-risk symptoms and designing treatment interventions.
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• Alcohol and cannabis are the most frequently reported substances used by 
clinical high-risk individuals.
• Cannabis use that is not impairing does not predict conversion to psychosis.
• Cannabis misuse (abuse or dependence) is associated with psychosis conversion 
when examined in isolation, but this relationship is weakened when alcohol use 
is also considered.
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• Information on substance use frequency, recency, and use over follow-up was 
not available and may have impacted outcomes.
• Rates of alcohol and cannabis use may be most applicable to North American 
samples.
• This sample had low rates of substance use other than alcohol and cannabis, 
which limited our ability to examine the impact of other substances on 
conversion to psychosis.
Auther et al. Page 13














Kaplan–Meier survival analysis depicting time to conversion (in months) for high-risk 
subjects with no cannabis use vs. cannabis use without impairment vs. cannabis abuse/
dependence.
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Table 1
Rates of lifetime substance use in high-risk subjects
No use Use without impairment Abuse Dependence
Substance N (%) N (%) N (%) N (%)
Alcohol 187 (54.7) 110 (32.2) 34 (9.9) 11 (3.2)
Cannabis 211 (61.9) 63 (18.5) 45 (13.2) 22 (6.5)
Hallucinogens 298 (87.4) 36 (10.6) 4 (1.2) 3 (0.9)
Cocaine 317 (92.7) 15 (4.4) 4 (1.2) 6 (1.8)
Stimulants 319 (93.5) 13 (3.8) 5 (1.5) 4 (1.2)
Opioids 328 (96.2) 12 (3.5) 1 (0.3) 0
Hypnotics 329 (96.5) 8 (2.3) 3 (0.9) 1 (0.3)
Other 321 (94.1) 14 (4.1) 4 (1.2) 2 (0.6)
Total N = 341 for all substances except for alcohol and cocaine (N = 342).
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